HORSHOLM, Denmark--(BUSINESS WIRE)--LifeCycle Pharma A/S (OMX:LCP), an emerging specialty pharmaceutical company focused on developing and commercializing differentiated versions of existing drugs in large therapeutic areas such as cardiovascular disease, organ transplantation and immunosuppression, including recently Food and Drug Administration (“FDA”) approved LCP-FenoChol, a fenofibrate for the treatment of hyperlipidemia and hypertriglyceridemia, today announced that Francesca DeMartino has been named Director, Investor Relations and Corporate Communications, effective September 4, 2007.
